Online inquiry

IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3526MR)

This product GTTS-WQ3526MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3526MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1783MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ4726MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ15954MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11441MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ1202MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ5784MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ1036MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9712MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW